"Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?"

Current Treatment Options in Oncology

Volumn 8, Issue 1, 2007, Pages 28-37

  Hann, Christine L ^a   Brahmer, Julie R ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; K RAS PROTEIN; PACLITAXEL; PLACEBO; RAS PROTEIN; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ADENOCARCINOMA; ASIAN; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SENSITIVITY; ETHNICITY; GENE AMPLIFICATION; GENE DUPLICATION; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MONOTHERAPY; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; SMOKING; ASIAN AMERICAN; DRUG ANTAGONISM; ETHNOLOGY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; LUNG TUMOR; METABOLISM; METHODOLOGY; MUTATION; ONCOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN AMERICANS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MEDICAL ONCOLOGY; MUTATION; QUINAZOLINES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING;

EID: 36049010648     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-007-0024-2     Document Type: Review

References (59)

1. American Cancer Society (2006) Cancer Facts and Figures 2006. American Cancer Society.
2. Drugs FDA (2006).
3. Kris MG, Natale RB, Herbst RS, et al.: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. Jama 2003, 290:2149-2158
4. Fukuoka M, Yano S, Giaccone G, et al.: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003, 21:2237-2246
5. Perez-Soler R, Chachoua A, Hammond LA, et al.: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004, 22:3238-3247
6. Thatcher N, Chang A, Parikh P, et al.: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366:1527-1537
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132
8. Giaccone G, Herbst RS, Manegold C, et al.: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 2004, 22:777-784
9. Gatzemeier U, Pluzanska A, Szczesna A, et al.: Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol, 2004 ASCO Annual Meeting Proceedings 2004, 22, 7010.
10. Herbst RS, Giaccone G, Schiller JH, et al.: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004, 22:785-794
11. HerAst RS, Prager D, Hermann R, et al.: TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:5892-5899
12. Scaltriti M, Baselga J: The epidermal grAwth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006, 12:5268-5272
13. Hirsch FR, Varella-Garcia M, Bunn PA Jr., et al.: Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21:3798-3807
14. Kaneda H, Kurata T, Tamura K, et al.: A phase I study of irinotecan in combination with amrubicin for advanced lung cancer patients. Anticancer Res 2006, 26:2479-2485
15. Bezjak A, Tu D, Seymour L, et al.: Symptom improvement in lung cancer patients treated with erlotinib: Quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2006, 24:3831-3837
16. Gatzemeier U, Heller A, Foernzler D, et al.: Exploratory analyses of HER1/EGFR, K-ras mutations and other molecular markers in tumors of patients with NSCLC treated with chemotherapy with or without erlotinib (Tarceva) (TALENT-phase III). J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 2005, 23, 7028. http://www.asco.org/portal/site/ASCO/ menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview= abst_detail_view&confID=34&abstractID=31779
17. Giaccone G, Gallegos Ruiz M, Le Chevalier T, et al.: Erlotinib for frontline treatment of advanced non-small cell lung cancer: A phase II study. Clin Cancer Res 2006, 12:6049-6055
18. Lilenbaum R, Axelrod R, Thoas S, et al.: Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I 2006, 24, 7022.
19. Miller VA, Kris MG, Shah N, et al.: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004, 22:1103-1109
20. Janne PA, Gurubhagavatula S, Yeap BY, et al.: Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer 2004, 44:221-230
21. Haringhuizen A, van Tinteren H, Vaessen HF, et al.: Gefitinib as a last treatment option for non-small-cell lung cancer: Durable disease control in a subset of patients. Ann Oncol 2004, 15:786-792
22. Simon GR, Ruckdeschel JC, Williams C, et al.: Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: Experience from a single institution. Cancer Control 2003, 10:388-395
23. Argiris A, Mittal N: Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. Lung Cancer 2004, 43:317-322
24. Park J, Park BB, Kim JY, et al.: Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. Clin Cancer Res 2004, 10:4383-4388
25. Tsao MS, Sakurada A, Cutz JC, et al.: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005, 353:133-144
26. Lynch TJ, Bell DW, Sordella R, et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139
27. Paez JG, Janne PA, Lee JC, et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500
28. Pao W, Miller V, Zakowski M, et al.: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101:13306-13311
29. Huang SF, Liu HP, Li LH, et al.: High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004, 10:8195-8203
30. Kosaka T, Yatabe Y, Endoh H, et al.: Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res 2004, 64:8919-8923
31. Shigematsu H, Lin L, Takahashi T, et al.: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97:339-346
32. Janne PA, Johnson BE: Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 2006, 12:4416s-4420s
33. Han SW, Kim TY, Hwang PG, et al.: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005, 23:2493-2501
34. Mitsudomi T, Kosaka T, Endoh H, et al.: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005, 23:2513-2520
35. Takano T, Ohe Y, Sakamoto H, et al.: Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23:6829-6837
36. Cortes-Funes H, Gomez C, Rosell R, et al.: Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 2005, 16:1081-1086
37. Taron M, Ichinose Y, Rosell R, et al.: Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005, 11:5878-5885
38. Bell DW, Lynch TJ, Haserlat SM, et al.: Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005, 23:8081-8092
39. Eberhard DA, Johnson BE, Amler LC, et al.: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23:5900-5909
40. Riely GJ, Politi KA, Miller VA, Pao W: Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006, 12:7232-7241
41. Shigematsu H, Gazdar AF: Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006, 118:257-262
42. Shih JY, Gow CH, Yang PC: EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. N Engl J Med 2005, 353:207-208
43. Bell DW, Gore I, Okimoto RA, et al.: Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 2005, 37:1315-1316
44. Balak MN, Gong Y, Riely GJ, et al.: Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006, 12:6494-6501
45. Sordella R, Bell DW, Haber DA, Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305:1163-1167
46. Riely GJ, Pao W, Pham D, et al.: Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006, 12:839-844
47. Jackman DM, Yeap BY, Sequist LV, et al.: Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006, 12:3908-3914
48. Paz-Ares L, Sanchez M, Garcia-Velasco A, et al. A propective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I 2006, 24, 7020.
49. Nakagawa K: Clinical development of EGFR-tyrosine kinase inhibitors in Japan. Cancer Chemother Pharmacol 2006 58(Suppl 7):33-37
50. Hirsch FR, Varella-Garcia M, McCoy J, et al.: Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study. J Clin Oncol 2005, 23:6838-6845
51. Cappuzzo F, Hirsch FR, Rossi E, et al.: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005, 97:643-655
52. Cappuzzo F, Toschi L, Trisolini R, et al. Clinical and biological effects of gefitinib in EGFR RISH+/Phospho-Akt+ or never smoker non-small cell lung cancer (NSCLC): Preliminary results of the ONCOBELL trial J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I 2006, 24, 7023.
53. Ahrendt SA, Decker PA, Alawi EA, et al.: Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001, 92:1525-1530
54. Pao W, Wang TY, Riely GJ, et al.: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005, 2:e17.
55. Thomas SK, Fossella FV, Liu D, et al.: Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer 2006, 7:326-331
56. Ho C, Murray N, Laskin J, et al.: Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America. Lung Cancer 2005, 49:225-231
57. Chen YM, Perng RP, Tsai CM: Gefitinib treatment is highly effective in non-small-cell lung cancer patients failing previous chemotherapy in Taiwan: A prospective phase II study. J Chemother 2005, 17:679-684
58. Lee DH, Han JY, Kim HT, Lee JS: Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: Retrospective analysis of 575 Korean patients. Lung Cancer 2006, 53:339-345
59. Clark GM, Zborowski DM, Santabarbara P, et al.: Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer, 2006, 7:389-394